FREQ - Frequency Therapeutics GAAP EPS of -$0.67

Frequency Therapeutics press release (NASDAQ:FREQ): Q1 GAAP EPS of -$0.67. Cash, cash equivalents and marketable securities as of March 31, 2022, were $124.8M. These resources are sufficient to fund the ongoing Phase 2b clinical program for the Company’s lead candidate for hearing restoration (FX-322); a second pre-clinical program for hearing restoration (FX-345); and a pre-clinical program for remyelination in MS. The company believes its existing cash, cash equivalents and marketable securities will be sufficient to fund its operations into 2024.

For further details see:

Frequency Therapeutics GAAP EPS of -$0.67